8-K Announcements
6Material company update
Apr 30, 2026·SEC
Material company update
Feb 26, 2026·SEC
Material company update
Jan 8, 2026·SEC
Phathom Pharmaceuticals, Inc.(PHAT)Earnings, Financials & Key Ratios
PHAT•NASDAQ
$12.67
$1.01B mkt cap·Price updated May 6, 2026
AboutPhathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.Show more
- Revenue$175M+216.9%
- EBITDA-$159M+42.4%
- Net Income-$221M+33.8%
- EPS (Diluted)-3.03+42.7%
- Gross Margin87.09%+1.8%
- EBITDA Margin-91%+81.8%
- Operating Margin-91.36%+81.8%
- Net Margin-126.35%+79.1%
- Interest Coverage-2.35+35.5%
PHAT Key Insights
Phathom Pharmaceuticals, Inc. (PHAT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Profits declining 11.4% over 5 years
- ✗Negative free cash flow
- ✗Shares diluted 15.4% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
PHAT Price & Volume
Phathom Pharmaceuticals, Inc. (PHAT) stock price & volume — 10-year historical chart
Loading chart...
PHAT Growth Metrics
Phathom Pharmaceuticals, Inc. (PHAT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM150.3%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM63.29%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM59.54%
Return on Capital
10 Years-76.74%
5 Years-80.39%
3 Years-74.83%
Last Year-76.24%
PHAT Recent Earnings
Phathom Pharmaceuticals, Inc. (PHAT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 5/12 qtrs (50%)
Q2 2026Latest
Apr 30, 2026EPS
$0.37
Est $0.17
-117.6%
Revenue
$58M
Est $56M
+4.3%
Q1 2026
Feb 26, 2026EPS
$0.16
Est $0.32
+49.9%
Revenue
$58M
Est $57M
+0.7%
Q4 2025
Oct 30, 2025EPS
$0.15
Est $0.30
+50.0%
Revenue
$50M
Est $57M
-13.8%
Q3 2025
Aug 7, 2025EPS
$0.79
Est $0.76
-3.9%
Revenue
$40M
Est $47M
-15.5%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 30, 2026 | $0.37vs $0.17-117.6% | $58Mvs $56M+4.3% |
| Q1 2026 | Feb 26, 2026 | $0.16vs $0.32+49.9% | $58Mvs $57M+0.7% |
| Q4 2025 | Oct 30, 2025 | $0.15vs $0.30+50.0% | $50Mvs $57M-13.8% |
| Q3 2025 | Aug 7, 2025 | $0.79vs $0.76-3.9% | $40Mvs $47M-15.5% |
Based on last 12 quarters of dataView full earnings history →
PHAT Peer Comparison
Phathom Pharmaceuticals, Inc. (PHAT) competitors in Commercial Specialty Pharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ACAD | 3.68B | 21.48 | 9.38 | 11.87% | 36.49% | 41.9% | 0.04 | |
 SUPN | 2.96B | 51.45 | -75.66 | 8.63% | -3.74% | -2.73% | 0.04 | |
 PRGO | 1.69B | 12.26 | -1.19 | -2.75% | -43.5% | -50.65% | 1.35 | |
 IRWD | 787.57M | 4.83 | 32.20 | -15.72% | 8.11% | |||
 PTGX | 6.63B | 103.97 | -50.72 | -89.41% | -6.48% | -17.76% | 0.02 | |
 MDGL | 12.38B | 539.73 | -42.00 | 432.05% | -27.32% | -50.15% | 0.59 | |
 TAK | 52.82B | 16.72 | 77.66 | 7.45% | 2.56% | 1.5% | 0.65 | |
 AZN | 286.68B | 184.92 | 28.28 | 8.63% | 17.19% | 22.24% | 0.61 |
Compare PHAT vs Peers
Phathom Pharmaceuticals, Inc. (PHAT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PHAT Income Statement
Phathom Pharmaceuticals, Inc. (PHAT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 682K | 55.25M | 175.11M | 204.89M |
| Revenue Growth % | - | - | - | - | - | - | 8001.47% | 216.93% | 150.3% |
| Cost of Goods Sold | 0 | 8K | 300K | 521K | 620K | 167K | 7.97M | 22.6M | 30.87M |
| COGS % of Revenue | - | - | - | - | - | 24.49% | 14.43% | 12.91% | - |
| Gross Profit | 0▲ 0% | -8K▲ 0% | -300K▼ 3650.0% | -521K▼ 73.7% | -620K▼ 19.0% | 515K▲ 183.1% | 47.28M▲ 9080.4% | 152.51M▲ 222.6% | 174.02M▲ 0% |
| Gross Margin % | - | - | - | - | - | 75.51% | 85.57% | 87.09% | 84.93% |
| Gross Profit Growth % | - | - | -3650% | -73.67% | -19% | 183.06% | 9080.39% | 222.58% | - |
| Operating Expenses | 1.23M | 106.22M | 125.36M | 134.56M | 171.82M | 167.83M | 324.75M | 312.5M | 270.62M |
| OpEx % of Revenue | - | - | - | - | - | 24608.06% | 587.75% | 178.46% | - |
| Selling, General & Admin | 1.21M | 6.94M | 27.22M | 62.22M | 100.38M | 117.93M | 290.66M | 279.72M | 239.25M |
| SG&A % of Revenue | - | - | - | - | - | 17291.5% | 526.07% | 159.74% | - |
| Research & Development | 20K | 99.27M | 98.15M | 72.34M | 71.44M | 49.9M | 34.08M | 32.78M | 31.37M |
| R&D % of Revenue | - | - | - | - | - | 7316.57% | 61.68% | 18.72% | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -1.23M▲ 0% | -106.22M▼ 8570.6% | -125.67M▼ 18.3% | -135.08M▼ 7.5% | -172.44M▼ 27.7% | -167.31M▲ 3.0% | -277.47M▼ 65.8% | -159.99M▲ 42.3% | -96.6M▲ 0% |
| Operating Margin % | - | - | - | - | - | -24532.55% | -502.18% | -91.36% | -47.15% |
| Operating Income Growth % | - | -8570.61% | -18.31% | -7.49% | -27.66% | 2.97% | -65.84% | 42.34% | - |
| EBITDA | 0 | -106.21M | -125.36M | -134.56M | -171.82M | -166.74M | -276.67M | -159.35M | -96.14M |
| EBITDA Margin % | - | - | - | - | - | -24448.24% | -500.75% | -91% | -46.92% |
| EBITDA Growth % | - | - | -18.04% | -7.33% | -27.69% | 2.96% | -65.93% | 42.4% | 66.34% |
| D&A (Non-Cash Add-back) | 1.23M | 8K | 300K | 521K | 620K | 575K | 795K | 633K | 456K |
| EBIT | -1.27M | -250.95M | -124.49M | -137.09M | -170.42M | -159.62M | -262.32M | -159.99M | -81.12M |
| Net Interest Income | 0 | -3.09M | -3.49M | -6.75M | -25.17M | -34.09M | -56.85M | -61.07M | -45.64M |
| Interest Income | 0 | 1.09M | 1.09M | 41K | 2.13M | 7.88M | 15.16M | 7.04M | 6.14M |
| Interest Expense | 13K | 4.18M | 4.58M | 6.79M | 27.3M | 41.97M | 72.01M | 68.11M | 34.25M |
| Other Income/Expense | -63K | -148.92M | -3.4M | -8.8M | -25.28M | -34.28M | -56.86M | -61.26M | -45.81M |
| Pretax Income | -1.29M▲ 0% | -255.13M▼ 19708.3% | -129.07M▲ 49.4% | -143.88M▼ 11.5% | -197.72M▼ 37.4% | -201.59M▼ 2.0% | -334.33M▼ 65.8% | -221.25M▲ 33.8% | -126.93M▲ 0% |
| Pretax Margin % | - | - | - | - | - | -29558.94% | -605.09% | -126.35% | -61.95% |
| Income Tax | 13K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | -1.01% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -1.29M▲ 0% | -209.74M▼ 16184.5% | -129.07M▲ 38.5% | -143.88M▼ 11.5% | -197.72M▼ 37.4% | -201.59M▼ 2.0% | -334.33M▼ 65.8% | -221.25M▲ 33.8% | -126.93M▲ 0% |
| Net Margin % | - | - | - | - | - | -29558.94% | -605.09% | -126.35% | -61.95% |
| Net Income Growth % | - | -16184.47% | 38.46% | -11.48% | -37.42% | -1.96% | -65.84% | 33.82% | 63.29% |
| Net Income (Continuing) | -1.29M | -255.13M | -129.07M | -143.88M | -197.72M | -201.59M | -334.33M | -221.25M | -126.93M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.15▲ 0% | -8.48▼ 5553.3% | -4.01▲ 52.7% | -4.00▲ 0.2% | -5.70▼ 42.5% | -3.93▲ 31.1% | -5.29▼ 34.6% | -3.03▲ 42.7% | -1.55▲ 0% |
| EPS Growth % | - | -5553.33% | 52.71% | 0.25% | -42.5% | 31.05% | -34.61% | 42.72% | 59.54% |
| EPS (Basic) | -0.15 | -8.48 | -4.01 | -4.00 | -5.70 | -3.93 | -5.29 | -3.03 | - |
| Diluted Shares Outstanding | 8.58M | 24.73M | 33.23M | 37M | 39.12M | 51.29M | 63.18M | 72.92M | 82.05M |
| Basic Shares Outstanding | 8.58M | 24.73M | 33.23M | 37M | 39.12M | 51.29M | 63.18M | 72.92M | 82.05M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
PHAT Balance Sheet
Phathom Pharmaceuticals, Inc. (PHAT) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 902K | 255.6M | 291.37M | 186.53M | 160.51M | 397.43M | 360.13M | 228.97M | 276.57M |
| Cash & Short-Term Investments | 879K | 243.76M | 287.5M | 183.26M | 155.38M | 381.39M | 297.26M | 129.97M | 180.9M |
| Cash Only | 879K | 243.76M | 287.5M | 183.26M | 155.38M | 381.39M | 297.26M | 129.97M | 180.9M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 82K | 0 | 0 | 1.64M | 38.8M | 78.13M | 80.72M |
| Days Sales Outstanding | - | - | - | - | - | 876.11 | 256.3 | 162.85 | 118.42 |
| Inventory | 0 | 0 | -82K | 0 | 0 | 1.21M | 3.21M | 5.52M | 6.51M |
| Days Inventory Outstanding | - | - | - | - | - | 2.64K | 146.86 | 89.12 | 56.36 |
| Other Current Assets | 0 | 0 | 3.87M | 3.27M | 5.13M | 13.19M | 20.87M | 15.35M | 8.44M |
| Total Non-Current Assets | 0 | 1.58M | 3.74M | 2.9M | 4.3M | 16.41M | 18.18M | 30.18M | 28.55M |
| Property, Plant & Equipment | 0 | 1.4M | 3.36M | 2.56M | 3.49M | 3.62M | 2.09M | 3.67M | 3.52M |
| Fixed Asset Turnover | - | - | - | - | - | 0.19x | 26.45x | 47.75x | 62.30x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 505K | 0 | 2.86M | 0 | 5.72M |
| Other Non-Current Assets | 0 | 181K | 384K | 341K | 299K | 12.79M | 13.23M | 26.51M | 103.7M |
| Total Assets | 902K▲ 0% | 257.18M▲ 28412.0% | 295.11M▲ 14.7% | 189.43M▼ 35.8% | 164.81M▼ 13.0% | 413.84M▲ 151.1% | 378.32M▼ 8.6% | 259.15M▼ 31.5% | 305.12M▲ 0% |
| Asset Turnover | - | - | - | - | - | 0.00x | 0.15x | 0.68x | 0.78x |
| Asset Growth % | - | 28411.97% | 14.75% | -35.81% | -13% | 151.1% | -8.58% | -31.5% | -87.39% |
| Total Current Liabilities | 2.19M | 3.75M | 55.52M | 18.92M | 26.24M | 38.78M | 85.73M | 132.04M | 125.04M |
| Accounts Payable | 55K | 699K | 16.78M | 5.15M | 10M | 12.6M | 10.51M | 4.98M | 6.37M |
| Days Payables Outstanding | - | 31.89K | 20.42K | 3.61K | 5.89K | 27.54K | 481.01 | 80.48 | 48.57 |
| Short-Term Debt | 1.95M | 0 | 7.35M | 0 | 0 | 0 | 19.78M | 648K | 667K |
| Deferred Revenue (Current) | -1.95M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 413K | 0 | 0 | 0 | 20.43M | 54.94M | 126.41M | 118.01M |
| Current Ratio | 0.41x | 68.20x | 5.25x | 9.86x | 6.12x | 10.25x | 4.20x | 1.73x | 1.73x |
| Quick Ratio | 0.41x | 68.20x | 5.25x | 9.86x | 6.12x | 10.22x | 4.16x | 1.69x | 1.69x |
| Cash Conversion Cycle | - | - | - | - | - | -24.02K | -77.85 | 171.49 | 126.21 |
| Total Non-Current Liabilities | 0 | 25.48M | 45.32M | 98.35M | 213.39M | 447.82M | 546.17M | 565.27M | 517.03M |
| Long-Term Debt | 0 | 22.78M | 39.63M | 89.67M | 95.26M | 137.84M | 534.67M | 2.06M | 1.96M |
| Capital Lease Obligations | 0 | 635K | 1.56M | 1.18M | 1.1M | 462K | 0 | 0 | 589K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 2.06M | 4.13M | 7.5M | 117.03M | 309.52M | 11.5M | 563.21M | 1.66B |
| Total Liabilities | 2.19M | 29.22M | 100.84M | 117.28M | 239.62M | 486.6M | 631.9M | 697.32M | 642.08M |
| Total Debt | 1.95M | 23.57M | 49.02M | 91.34M | 97.07M | 139.03M | 554.95M | 2.71M | 2.63M |
| Net Debt | 1.07M | -220.19M | -238.48M | -91.92M | -58.31M | -242.36M | 257.68M | -127.26M | -178.28M |
| Debt / Equity | - | 0.10x | 0.25x | 1.27x | - | - | - | - | -0.01x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | -0.03x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | 1.85x |
| Interest Coverage | -98.08x | -60.08x | -27.17x | -20.20x | -6.24x | -3.80x | -3.64x | -2.35x | -2.37x |
| Total Equity | -1.29M▲ 0% | 227.96M▲ 17825.9% | 194.27M▼ 14.8% | 72.16M▼ 62.9% | -74.81M▼ 203.7% | -72.76M▲ 2.7% | -253.58M▼ 248.5% | -438.17M▼ 72.8% | -336.95M▲ 0% |
| Equity Growth % | - | 17825.89% | -14.78% | -62.86% | -203.68% | 2.75% | -248.52% | -72.79% | -271.75% |
| Book Value per Share | -0.15 | 9.22 | 5.85 | 1.95 | -1.91 | -1.42 | -4.01 | -6.01 | -4.11 |
| Total Shareholders' Equity | -1.29M | 227.96M | 194.27M | 72.16M | -74.81M | -72.76M | -253.58M | -438.17M | -336.95M |
| Common Stock | 0 | 2K | 3K | 3K | 3K | 5K | 6K | 6K | 7K |
| Retained Earnings | -1.29M | -256.42M | -385.49M | -529.37M | -727.09M | -928.68M | -1.26B | -1.48B | -1.51B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PHAT Cash Flow Statement
Phathom Pharmaceuticals, Inc. (PHAT) cash flow — operating, investing & free cash flow history
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -1.02M | -36.51M | -69.69M | -148.46M | -146.53M | -137.58M | -266.77M | -166.78M | -166.78M |
| Operating CF Margin % | - | - | - | - | - | -20173.02% | -482.82% | -95.24% | - |
| Operating CF Growth % | - | -3468.91% | -90.87% | -113.03% | 1.3% | 6.11% | -93.9% | 37.48% | 262.79% |
| Net Income | -1.29M | -255.13M | -129.07M | -143.88M | -197.72M | -201.59M | -334.33M | -221.25M | -126.93M |
| Depreciation & Amortization | 0 | 8K | 323K | 521K | 620K | 575K | 795K | 633K | 566K |
| Stock-Based Compensation | 0 | 406K | 5.84M | 16.81M | 24.13M | 45.02M | 24.05M | 28.72M | 28.71M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 50K | 227.73M | 1.5M | 5.41M | 21M | 32.06M | 58.01M | 37.5M | 33.99M |
| Working Capital Changes | 215K | -9.52M | 51.72M | -27.32M | 5.44M | -13.64M | -15.3M | -12.38M | -3.46M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | -1.64M | -37.16M | -39.33M | -44.36M |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | -9.44M | -6.14M | -11.78M | 1.21M |
| Change in Payables | 225K | 2.27M | 24.01M | -9.79M | 8.68M | 6.41M | 34.94M | 34.1M | 37.94M |
| Cash from Investing | 0 | -25.25M | -1.04M | -328K | -1.04M | -1.63M | -135K | -229K | -272K |
| Capital Expenditures | 0 | -132K | -1.04M | -328K | -1.04M | -1.63M | -135K | -229K | 18K |
| CapEx % of Revenue | - | - | - | - | - | 239.59% | 0.24% | 0.13% | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | -25.12M | 0 | 0 | 0 | 0 | 0 | 0 | -290K |
| Cash from Financing | 1.9M | 304.65M | 114.46M | 44.71M | 120.04M | 367.58M | 182.77M | -288K | 66.35M |
| Debt Issued (Net) | 1.9M | 113.17M | 25M | 42.76M | 95.45M | 39.32M | 59.4M | 0 | 0 |
| Equity Issued (Net) | 0 | 191.47M | 88.83M | 0 | 24.6M | 155.46M | 121.78M | 1.64M | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 2K | 0 | 629K | 1.94M | 0 | 172.8M | 1.6M | -1.93M | 66.35M |
| Net Change in Cash | 879K▲ 0% | 242.89M▲ 27532.1% | 43.73M▼ 82.0% | -104.08M▼ 338.0% | -27.87M▲ 73.2% | 228.37M▲ 919.3% | -84.13M▼ 136.8% | -167.29M▼ 98.8% | -31.41M▲ 0% |
| Free Cash Flow | -1.02M▲ 0% | -61.76M▼ 5937.1% | -70.73M▼ 14.5% | -148.78M▼ 110.4% | -147.57M▲ 0.8% | -139.21M▲ 5.7% | -266.9M▼ 91.7% | -166.78M▲ 37.5% | -97.4M▲ 0% |
| FCF Margin % | - | - | - | - | - | -20412.61% | -483.07% | -95.24% | -47.54% |
| FCF Growth % | - | -5937.15% | -14.52% | -110.36% | 0.82% | 5.66% | -91.72% | 37.52% | 65.54% |
| FCF per Share | -0.12 | -2.50 | -2.13 | -4.02 | -3.77 | -2.71 | -4.22 | -2.29 | -2.29 |
| FCF Conversion (FCF/Net Income) | 0.79x | 0.17x | 0.54x | 1.03x | 0.74x | 0.68x | 0.80x | 0.75x | 0.77x |
| Interest Paid | 0 | 1.01M | 3.46M | 4.07M | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PHAT Key Ratios
Phathom Pharmaceuticals, Inc. (PHAT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -185.07% | -61.14% | -108.01% | - | - | - | - | 31.66% |
| Return on Invested Capital (ROIC) | -2110.79% | - | - | - | - | - | - | 17.93% |
| Gross Margin | - | - | - | - | 75.51% | 85.57% | 87.09% | 84.93% |
| Net Margin | - | - | - | - | -29558.94% | -605.09% | -126.35% | -61.95% |
| Debt / Equity | 0.10x | 0.25x | 1.27x | - | - | - | - | -0.01x |
| Interest Coverage | -60.08x | -27.17x | -20.20x | -6.24x | -3.80x | -3.64x | -2.35x | -2.37x |
| FCF Conversion | 0.17x | 0.54x | 1.03x | 0.74x | 0.68x | 0.80x | 0.75x | 0.77x |
| Revenue Growth | - | - | - | - | - | 8001.47% | 216.93% | 150.3% |
PHAT SEC Filings & Documents
Phathom Pharmaceuticals, Inc. (PHAT) SEC filings — annual & quarterly reports (10-K, 10-Q)
PHAT Frequently Asked Questions
Phathom Pharmaceuticals, Inc. (PHAT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Phathom Pharmaceuticals, Inc. (PHAT) reported $204.9M in revenue for fiscal year 2025.
Phathom Pharmaceuticals, Inc. (PHAT) grew revenue by 216.9% over the past year. This is strong growth.
Phathom Pharmaceuticals, Inc. (PHAT) reported a net loss of $126.9M for fiscal year 2025.
Dividend & Returns
Phathom Pharmaceuticals, Inc. (PHAT) had negative free cash flow of $97.4M in fiscal year 2025, likely due to heavy capital investments.
Explore More PHAT
Phathom Pharmaceuticals, Inc. (PHAT) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates